RxDoctor Payments Data

Angela Sanford, MD

Geriatric Medicine · Saint Louis, MONPI 1710115290

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,212 of the $15,189 with a category attached, or 80.4%. 6 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 54.2% of the total. Reporting peaked in 2019 at $8,102 and has fallen 91.8% since, to $667 in 2025. Among geriatric medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,189in general payments, 2019–2025

Across 22 payments — averaging $690.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$8K
  • Lundbeck LLC$6K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$545
  • Neurocrine Biosciences, Inc.$122
  • Janssen Scientific Affairs, LLC$39
  • Novo Nordisk$31

What the payments were for

  • Consulting fees$12,21280%
  • Travel & lodging$2,23215%
  • Food & beverage$7445%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,189 in reported general payments places this provider in the 95th percentile of 76 geriatric medicine providers in Missouri.

See all geriatric medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$75,257
Medicare patients
245
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban488$150,249
JardianceEmpagliflozin17$15,499
TradjentaLinagliptin62$15,071
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$13,079
OzempicSemaglutide11$11,160
Breo ElliptaFluticasone/Vilanterol21$9,152
XareltoRivaroxaban16$8,637
Mesalamine11$8,174
Pantoprazole Sodium305$4,345
Aripiprazole30$4,250
Atorvastatin Calcium385$4,133
Buspirone Hcl295$3,925
Mirtazapine193$3,580
Alphagan PBrimonidine Tartrate17$3,563
Potassium Chloride100$3,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$11,16011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 76 geriatric medicine providers in Missouri.

Other geriatric medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →